Skip to main content
Premium Trial:

Request an Annual Quote

Biocept NRAS Liquid Biopsy Test

Biocept has launched a new Target Selector liqud biopsy assay for mutations in the NRAS oncogene. According to the company, the NRAS mutations targeted by the test are associated with multiple cancer types such as metastatic melanoma, colorectal and lung cancer. The new test, like Biocept's other clinical assays, is run in its CLIA-certified San Diego lab. The new product brings the company's total number of Target Selector tests to 15.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.